Pharmacology of photosensitizer in rats with metastatic breast cancer: time point determination for photodynamic therapy (PDT) treatment of vertebral metastases

2005 ◽  
Author(s):  
Margarete K. Akens ◽  
Albert J. M. Yee ◽  
Lothar Lilge ◽  
Shane Burch ◽  
Cari Whyne ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Vertebral Metastases ◽  
Point Determination ◽  
Time Point

scholarly journals Photodynamic Therapy with Verteporfin for Choroidal Metastasis Refractory to Radiotherapy

2019 ◽  
Vol 12 (3) ◽  
pp. 861-865
Author(s):  
Raymond Zhou ◽  
David Reichstein
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Primary Breast Cancer ◽  
External Beam Radiotherapy ◽  
Metastatic Breast ◽  
Eye Disease ◽  
External Beam ◽  
Choroidal Metastasis

A 54-year old female with longstanding metastatic breast cancer was referred for management of choroidal metastases. She was first treated with external beam radiotherapy and experienced some response before later suffering progression of her eye disease. We then treated her using full fluence Photodynamic therapy (PDT) with Verteporfin, which resulted in regression of her lesions until she passed away due to other illnesses. This is the first documented successful application of PDT for choroidal metastasis from a primary breast cancer refractory to external beam radiotherapy.

In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid

2014 ◽  
Vol 11 (3) ◽  
pp. 426-433
Author(s):  
Margarete K. Akens ◽  
Lisa Wise-Milestone ◽  
Emily Won ◽  
Joerg Schwock ◽  
Albert J.M. Yee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Metastatic Breast ◽  
In Vivo Effects

scholarly journals Photodynamic therapy of intradermal metastatic breast cancer (literature review)

2019 ◽  
Vol 8 (3) ◽  
pp. 36-42
Author(s):  
R. I. Rakhimzhanova ◽  
N. A. Shanazarov ◽  
D. E. Turzhanova
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Therapeutic Effect ◽  
High Efficiency ◽  
Radiation Treatment ◽  
Metastatic Breast ◽  
Breast Metastases ◽  
The World ◽  
Promising Treatment

In recent years, an increase in the incidence of breast cancer has been observed throughout the world, and in 20% of cases, with the development of intradermal metastases. The possibilities of surgical and radiation treatment of intradermal breast metastases are quite limited, and the effectiveness of polychemotherapy using standard regimens does not exceed 22–27%, while the period of remission, in general, is only 2–3 months. Photodynamic therapy (PDT) is a promising treatment for intradermal metastases of breast cancer. The experience of using PDT in this nosology is quite limited, but the results show its high efficiency and safety. Thus, several Russian studies are devoted to assessing the effectiveness of PDT of intradermal breast metastases with Photolon, a chlorin series photosensitizer. According to the authors, the therapeutic effect was achieved in 85–97% of patients (the percentage of patients with full and partial effect was 73–85%). Studies on the effectiveness of PDT in patients with the same nosology using the Photosens photosensitizer show a slightly lower effectiveness – the therapeutic effect was achieved in 81.8% of cases, while the proportion of patients with full and partial effect was only about 50%. Several studies have been carried out abroad on models of metastatic breast cancer using new photosensitizers (e.g. sodium sinoporphyrin) and new combined PDT regimens (e.g. adjuvant PDT with fluorouracil or Capecitabine). The obtained results demonstrate the promise of new approaches: PDT with sodium sinoporphyrin inhibited the growth of both the tumor itself and its metastases; the use of adjuvant regimens led to an increase in the tumor cells differentiation in the animal model, the cessation of tumor and metastatic foci growth.

scholarly journals Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures

Diagnostics ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 398
Author(s):  
Mohammad Naghavi-Behzad ◽  
Charlotte Bjerg Petersen ◽  
Marianne Vogsen ◽  
Poul-Erik Braad ◽  
Malene Grubbe Hildebrandt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Survival Time ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Standardized Uptake Value ◽  
Metastatic Breast ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Time Point

This study aimed to compare the prognostic value of quantitative measures of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) for the response monitoring of patients with metastatic breast cancer (MBC). In this prospective study, 22 patients with biopsy-verified MBC diagnosed between 2011 and 2014 at Odense University Hospital (Denmark) were followed up until 2019. A dual-time-point FDG-PET/CT scan protocol (1 and 3 h) was applied at baseline, when MBC was diagnosed. Baseline characteristics and quantitative measures of maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), corrected SUVmean (cSUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and corrected TLG (cTLG) were collected. Survival time was analyzed using the Kaplan–Meier method and was regressed on MTV, TLG, and cTLG while adjusting for clinicopathological characteristics. Among the 22 patients included (median age: 59.5 years), 21 patients (95%) died within the follow-up period. Median survival time was 29.13 months (95% Confidence interval: 20.4–40 months). Multivariable Cox proportional hazards regression analyses of survival time showed no influence from the SUVmean, cSUVmean, or SUVmax, while increased values of MTV, TLG, and cTLG were significantly associated with slightly higher risk, with hazard ratios ranging between 1.0003 and 1.004 (p = 0.007 to p = 0.026). Changes from 1 to 3 h were insignificant for all PET measures in the regression model. In conclusion, MTV and TLG are potential prognostic markers for overall survival in MBC patients.

scholarly journals The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer

2020 ◽  
Vol 183 (3) ◽  
pp. 629-638
Author(s):  
Helena Harder ◽  
Valerie M. Shilling ◽  
Shirley F. May ◽  
David Cella ◽  
Peter Schmid ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Missing Data ◽  
Randomised Trial ◽  
Metastatic Breast ◽  
Initial Evaluation ◽  
Self Report ◽  
Sensitivity To Change ◽  
Pilot Testing ◽  
Time Point

Abstract Purpose Chemotherapy-induced diarrhoea (CID) is a common, but often underreported problem in patients with breast cancer that has a profound effect on quality of life. It is best measured from a patient’s perspective, but tools are limited. The aim of this study was to develop and evaluate the Diarrhoea Management Diary (DMD), a self-report measure to assess CID, use of self-management strategies and treatment adherence. Methods The DMD was constructed using an iterative process of instrument development: concept elicitation (literature review), item generation and reduction (cognitive debriefing), and pilot testing in the target population. After translation into eight languages, the DMD was used in an international randomised trial for women receiving lapatinib and capecitabine for metastatic breast cancer with or without prophylactic octreotide. Patterns of missing data and sensitivity to change were examined. Results The understandability and completeness of the 8-item DMD was confirmed in cognitive interviews and pilot testing. Practicability of the DMD was evaluated in 62 women with metastatic breast cancer (median age 57). Up to 68% reported CID at any given time-point, and 19% had diarrhoea at each time-point. Patients also described efficacy of different strategies for diarrhoea management. Missing data were associated with study discontinuation. DMD missing item response was 0.9%. Sensitivity to change was good at most assessment points. Conclusions Although further psychometric testing is recommended, initial evaluation of the DMD showed good content validity and practicability in international research with cancer patients.

Secondary malignancies developing during metastatic breast cancer treatment

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e12020-e12020
Author(s):  
N. M. Nikolic ◽  
Z. Tomasevic ◽  
S. Jelic
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Median Time ◽  
Radical Surgery ◽  
Metastatic Breast ◽  
Breast Cancer Treatment ◽  
Secondary Malignancies ◽  
High Burden ◽  
Histological Confirmation ◽  
Time Point

e12020 Background: Secondary malignancies (SM) developing during metastatic breast cancer (MBC) are obviously more complicated for diagnosis, potential surgery and for further MBC treatment. However, the frequency of SM during MBC is not well explored, in contrast to SM after nonmetastatic BC. The aim of this paper is to determine frequency of SM in MBC patients and to determine the percentage of surgically treated SM. Methods: Hospital charts of BC patients were retrospectively analyzed at the Institute for Oncology and Radiology of Serbia. Patients who developed SM at any time point after BC were included in this analysis. Patients with contra-lateral BC and acute leukemia were excluded. Patients with SM during MBC were separately analyzed. Results: A cohort of 50 BC patients with SM was identified. Median age was 50 (range 32–78 years) median time to SM was 65.3 months (range 1–276). Forty-six patients had histological confirmation of SM. In 30 patients SM developed during treatment for MBC. Four SM were not confirmed by biopsy due to SM site or high burden of MBC. Median age was 53.4 years (range 34–74), median time to SM development was 78.9 months, and median time to BC metastases was 60.1 months. The most frequent SM in MBC patient were lung (5), endometrial (4, all treated with tamoxifen), ovarian (3), thyroid (3), cervical (3), and colon carcinoma (2). Only 14 patients with SM (14/30: 46%) could be treated with radical surgery and SM did not influenced further MBC treatment. Conclusions: According to our experience, SM develops more frequently in MBC than in non MBC patients, representing 60% (30/50 patients) of all SM in BC patients; 46.6% (14/30) of SM diagnosed during MBC could be surgically resected, and does not influence further MBC treatment. No significant financial relationships to disclose.

scholarly journals CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer

2013 ◽  
Vol 7 (11-12) ◽  
pp. 897-905 ◽  
Author(s):  
Yumin Xia ◽  
Gaurav K. Gupta ◽  
Ana P. Castano ◽  
Pawel Mroz ◽  
Pinar Avci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Cpg Oligodeoxynucleotide ◽  
Immune Adjuvant
Sign in / Sign up

Export Citation Format

Share Document